Aridis Pharmaceuticals, Inc.

Equities

ARDS

US0403341045

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 18:32:20 26/06/2024 BST			5-day change	1st Jan Change
0.063 ^USD	-2.33%		-13.70%	-10.13%

06-24	Aridis Pharmaceuticals, Inc. Provides Corporate Update on Recent Developments	CI
2023	Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

ARIDIS PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

January 28, 2020 at 10:24 pm

Item 8.01 Other Events.

On January 28, 2020, Aridis Pharmaceuticals, Inc. announced that it presented a comprehensive profile of its APEXTM platform technology at the antibody and cell engineering conference 19th Annual PepTalk: The Protein Science Week on Friday, January 24, 2020 in San Diego, CA. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

Item 9.01. Financial Statements and Exhibits






(d) Exhibits.

99.1 Press Release of Aridis Pharmaceuticals, Inc. dated January 28, 2020

Latest news about Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals, Inc. Provides Corporate Update on Recent Developments	06-24	CI
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-03	CI
Certain Options of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	15/09/23	CI
Certain Warrants of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	15/09/23	CI
Certain Pre-Funded Warrant of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	15/09/23	CI
Certain Common Stock of Aridis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-SEP-2023.	15/09/23	CI
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/09/23	CI
Aridis Pharmaceuticals, Inc. Announces Resignation as Chief Financial Officer	09/08/23	CI
Aridis Pharmaceuticals, Inc.(OTCPK:ARDS) dropped from S&P TMI Index	21/07/23	CI
Sector Update: Health Care Stocks Steady Premarket Tuesday	18/07/23	MT
Aridis Pharmaceuticals, European Regulator Agree on Pneumonia Phase 3 Study Parameters; Shares Jump Premarket	18/07/23	MT
Aridis Pharmaceuticals, Inc.(OTCPK:ARDS) dropped from NASDAQ Composite Index	18/07/23	CI
Aridis Pharmaceuticals Reaches Agreement for Phase 3 Study of Pneumonia Treatment in Europe; Shares Jump After Hours	17/07/23	MT
Aridis Receives Agreement from the European Medicines Agency on the Clinical Study Design and A Single Confirmatory Phase 3 Study of AR-301	17/07/23	CI
Aridis Pharma Shares Rise 33% After FDA Product Designation for AR-301	12/07/23	DJ
Aridis Pharmaceuticals Gets FDA Product Designation for AR-301	12/07/23	DJ
Aridisâ€™ AR-301 Monoclonal Antibody is Among the First Biologics to Receive FDAâ€™s Qualified Infectious Diseases Product Designation	12/07/23	CI
Aridis Pharmaceuticals' AR-301 Eligible for Consideration Under FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs	20/06/23	CI
Aridis Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	08/06/23	CI
Sector Update: Health Care Stocks Advancing Late Wednesday	31/05/23	MT
Sector Update: Health Care	31/05/23	MT
Top Midday Gainers	31/05/23	MT
Aridis Pharma Shares Double After FDA Clearance to Start AR-301 Pneumonia Study	31/05/23	DJ
Aridis Pharmaceuticals, Inc. Receives Agreement from the FDA on a Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design	31/05/23	CI
Aridis Pharmaceuticals Files $3 Million Mixed Securities Registration Statement	23/05/23	MT

Chart Aridis Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Aridis Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is focused on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat life-threatening infections. The Company's product pipeline is comprised of fully human mAbs targeting specific pathogens associated with life-threatening bacterial and viral infections, primarily hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and cystic fibrosis. The Company's lead product candidates, AR-301 and AR-320, target the alpha toxin produced by the gram-positive bacteria Staphylococcus aureus (S. aureus), a common pathogen associated with HAP and VAP. The Companyâs clinical development activities are primarily focused on AR-301, AR-320, and AR-501. Its MabIgX and lPEX discovery platforms enable the Company to rapidly screen, identify, and optimize fully human therapeutic mAb product candidates directly from the B-cells of patients.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
ARIDIS PHARMACEUTICALS, INC.	-10.13%	3.09M
VERTEX PHARMACEUTICALS INCORPORATED	+16.49%	122B
REGENERON PHARMACEUTICALS, INC.	+21.73%	115B
ARGENX SE	+22.56%	26.64B
BIONTECH SE	-21.81%	19.91B
GENMAB A/S	-17.01%	16.32B
BEIGENE, LTD.	-18.81%	15.49B
WUXI APPTEC CO., LTD.	-44.74%	15.52B
SAREPTA THERAPEUTICS, INC.	+62.72%	14.83B
NEUROCRINE BIOSCIENCES, INC.	+3.09%	13.67B

Bio Therapeutic Drugs